Antonio Calles, Head of the Lung Cancer Unit at Hospital Ruber Internacional, shared a post on X:
“ELEVATE trial:
Ensartinib as adjuvant therapy in stage IB-IIIB ALK+ NSCLC. Positive for DFS. No OS provided.
Previous chemo adjuvant allowed but intriguingly, not significant for PFS in the forest plot (provide pic if you got it, please. I missed it).”
You can also read.
ESMO 2025 Day 1 Highlights Not to Miss
ESMO 2025 Day 2 Highlights Not to Miss
ESMO 2025 Day 3 Highlights Not to Miss
